

Short Title	Longer title or description	Local PI / contact	Links
AAV-B	This is a single visit research study testing antibodies against different types of virus called adeno-associated virus (AAV) in people with hemophilia B	Dr. Nicola Curry/Simon Fletcher	
BMN902	Haemophilia A – observation of treatment and bleeding episodes in severe patients.	Dr. Nicola Curry/Simon Fletcher	HRA
EHL registry	Evaluation of Real World Outcomes with Extended half-Life Concentrates for Routine Clinical Use in Haemophilia A and B: UK-EHL Outcome Registry (children and adults)	Dr. Nicola Curry/Anna Sanigorska	HRA
FIX-GT	Gene Therapy for Haemophilia B: A Phase I/II, Open label, Multicentre, Ascending Single Dose, Safety Study of a Novel Adeno-associated Viral Vector (FLT180a) in Patients With Haemophilia B	Dr. Susie Shapiro/Anna Sanigorska	NIHR HRA
FLIGHT trial	A multicentre randomised trial of First Line treatment pathways for newly diagnosed Immune Thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate	Dr. Sue Pavord/Chris Deane	HRA
GENA-25	Observational study of utilization of Octopharma Factor VIII concentrates in untreated/minimally treated Haemophilia A patients (children)	Dr. Georgina Hall/Marie Eales	HRA
GENEr8-1	Gene therapy for Haemophilia A patients with BMN270	Dr. Susie Shapiro/Anna Sanigorska	HRA NIHR
Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events	GARFIELD-VTE is global, prospective, observational, multi-centre VTE registry to be conducted in sequential cohorts, in order to observe temporal trends in management of VTE.	Dr. Nicola Curry/Chris Deane	HRA
NIHR BioResource	The National Institute for Health Research BioResource - Rare Diseases aims to recruit people who are affected by uncommon or rare diseases for the specific purpose of analysing their genotype and putting them on a database of people willing to assist with research. (children and adults)	Dr. David Keeling/Simon Fletcher	HRA Study site
Paradigm 5	Open label trial of long acting Factor in previously treated Haemophilia B patients (children)	Dr. Georgina Hall/Alice Wilkinson	HRA
Paradigm 6	Open label trial of long acting Factor in previously untreated Haemophilia B patients (children)	Dr. Georgina Hall/Alice Wilkinson	HRA

Short Title	Longer title or description	Local PI / contact	Links
Pathfinder8	Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients with Severe Haemophilia A (children and adults)	Dr. Nicola Curry/ Simon Fletcher	HRA
PRO-RBDD	European Network of Rare Bleeding Disorders - collect data on patients with the most severe types of rare bleeding disorders (RBDs), fibrinogen deficiency and FXIII deficiency, using a prospective observational cohort design.	Dr. Nicola Curry/ Simon Fletcher	HRA
StOP Haem A	Strategies for Optimising Prophylaxis –Clinical Utility and Accuracy of Model Predicted Factor VIII half-life and Trough Levels Compared to Current Recommended Prophylaxis Monitoring Strategies in Routine Clinical Practice in Adult Haemophilia A	Dr. Nicola Curry/ Simon Fletcher	HRA
TREATT	A double-blind, randomised controlled trial evaluating the safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia	Dr. Graham Collins/ Chris Deane	HRA NIHR
UK ITP Registry (adult)	United Kingdom Adult Idiopathic Thrombocytopenic Purpura (ITP) Registry: An Investigation of Disease Progression, Treatment Effectiveness, and Co-morbid Conditions	Prof. Mike Murphy/ Chris Deane	trial website
verITI-8	rFVIII Fc in Haemophilia A patients undergoing ITI	Dr. Georgina Hall/ Marie Eales	HRA